While Venn Life looks for a successor, Chief Executive Tony Richardson will take over Hartshorn's responsibilities.
Shares were down 1.7% on Wednesday at
Wed, 21st Mar 2018 11:03
While Venn Life looks for a successor, Chief Executive Tony Richardson will take over Hartshorn's responsibilities.
Shares were down 1.7% on Wednesday at
LONDON (Alliance News) - Venn Life Sciences Holdings PLC Tuesday said Chairman David Evans bought 210,000 shares at a price of 20.5 pence per share. Following this transaction, Evans now holds 289,033 shares. Shares in the clinical trial services company were trading flat at 20.5 penc
Read moreAIM-listed clinical research organisation Venn Life Sciences announced it has scored a multi-million euro contract with a major European biotechnology company. The agreement, which is spread out over a year and a half and spans over seven European countries as well as a number of US sites, will see
Read moreLONDON (Alliance News) - Venn Life Sciences Holdings PLC Friday posted a widened pretax loss in 2013, as it saw revenue decline, and announced a new contract win. The clinical research organisation posted a pretax loss of EUR1.8 million, widened from EUR1.2 million in the previous year, as
Read moreLONDON (Alliance News) - Venn Life Sciences Holdings PLC Friday said its Finance Director Paul Foulger has given notice of intention to resign from its board from April 14. The pharmaceutical and biotechnology company said Foulger now plans to pursue a full-time role within another public c
Read moreLONDON (Alliance News) - Shares have opened lower Friday on geopolitical worries ahead of the weekend, despite some good news for UK companies.
The US government on Thursday decided to lift the ban on BP from federal government contracts imposed after the Deepwater
LONDON (Alliance News) - Venn Life Sciences Holdings PLC Friday said it has raised GBP1 million before expenses by placing 5.3 million shares at 19 pence each, funds it will use to develop the Labskin and potential acne treatment it recently acquired. The placing is conditional on sharehold
Read moreLONDON (Alliance News) - Evocutis PLC saw its shares slide by a third Wednesday after it finally sold its assets after months of talks, leaving it as an investment shell. In a statement, Evocutis said it had sold all the intellectual property rights for its Labskin product and SYN1113 inves
Read moreVenn Life Sciences has won two contracts to provide a number of clinical trial-management services across Europe. The first contract is with a global pharmaceutical company to conduct a Phase IV drug interaction study and the second is with a leading US biotech company to manage a multi-national st
Read moreClinical research company Venn Life Sciences on Thursday said it expanded its operations with a new Russian business. The group has established Venn Russia, a joint venture with a local contract research organisation (CRO). The new arm will operate from offices in Moscow and will complement exist
Read more